Cargando…

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease

BACKGROUND: Type-2 diabetes mellitus (T2DM) is a risk factor for progressive non-alcoholic fatty liver disease (NAFLD). Drugs commonly prescribed in patients with T2DM may affect liver histology by interfering with lipid metabolism and insulin resistance/secretion. AIM: We studied if statins or anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nascimbeni, Fabio, Aron-Wisnewsky, Judith, Pais, Raluca, Tordjman, Joan, Poitou, Christine, Charlotte, Frederic, Bedossa, Pierre, Poynard, Thierry, Clément, Karine, Ratziu, Vlad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838660/ https://www.ncbi.nlm.nih.gov/pubmed/27110380 http://dx.doi.org/10.1136/bmjgast-2015-000075

Ejemplares similares

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
por: Poynard, Thierry, et al.
Publicado: (2015)

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2019)

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
por: Poynard, Thierry, et al.
Publicado: (2019)

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19
por: Deckmyn, Olivier, et al.
Publicado: (2022)

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
por: Poynard, Thierry, et al.
Publicado: (2012)

Association between metabolic syndrome and liver histology among NAFLD patients without diabetes
por: Kanwar, Pushpjeet, et al.
Publicado: (2016)

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study
por: Duseja, Ajay, et al.
Publicado: (2019)

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
por: Wood, Kayleigh L, et al.
Publicado: (2015)

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
por: Afonso, Marta B, et al.
Publicado: (2021)

Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression
por: Loyer, Xavier, et al.
Publicado: (2016)

Dysregulated activation of fetal liver programme in acute liver failure
por: Hyun, Jeongeun, et al.
Publicado: (2019)

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
por: Montagner, Alexandra, et al.
Publicado: (2016)

Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells
por: Dai, Zhen, et al.
Publicado: (2020)

Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites
por: Zhang, Xiang, et al.
Publicado: (2021)

Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary–secondary care interface
por: McPherson, Stuart, et al.
Publicado: (2023)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia
por: Chihota, Belinda Varaidzo, et al.
Publicado: (2022)

Mechanisms of liver disease in patients infected with HIV
por: Kaspar, Matthew B, et al.
Publicado: (2017)

Impact of steatosis and inflammation definitions on the performance of NASH tests
por: Poynard, Thierry, et al.
Publicado: (2018)

Changing trends of hospitalisation of liver cirrhosis in Beijing, China
por: Bao, Xiao-Yuan, et al.
Publicado: (2015)

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

Loss of hepatic Mboat7 leads to liver fibrosis
por: Thangapandi, Veera Raghavan, et al.
Publicado: (2021)

Does COVID-19 infection significantly affect liver transplantation? Results of liver transplantation in the COVID-19 era at a single, high-volume centre
por: Moradi, Alimohammad, et al.
Publicado: (2023)

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
por: Munteanu, Mona, et al.
Publicado: (2018)

COVID-19 and liver cancer: lost patients and larger tumours
por: Geh, Daniel, et al.
Publicado: (2022)

Effect of COVID-19 on presentations of decompensated liver disease in Scotland
por: Manship, Thomas, et al.
Publicado: (2022)

Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis
por: Salhab, Ahmad, et al.
Publicado: (2022)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease
por: Zambon Azevedo, Vittoria, et al.
Publicado: (2022)

The societal burden of chronic liver diseases: results from the COME study
por: Scalone, Luciana, et al.
Publicado: (2015)

TGF-β2 silencing to target biliary-derived liver diseases
por: Dropmann, Anne, et al.
Publicado: (2020)

Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
por: Asfari, Mohammad Maysara, et al.
Publicado: (2020)

Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure
por: Yang, Huayu, et al.
Publicado: (2021)

Scoping review of clinical practice guidelines on the management of benign liver tumours
por: Haring, Martijn P D, et al.
Publicado: (2021)

Prevalence, severity, duration and resolution of cholestasis after acute liver failure
por: Warming, Scott, et al.
Publicado: (2022)

Liver stiffness by transient elastography accompanies illness severity in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2020)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
por: Maev, Igor V, et al.
Publicado: (2020)

Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD
por: Al-Karaghouli, Mustafa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dgm98h5hig74b86aguebt7aijq